Next Article in Journal
The Isolation of Anaerobic and Facultative Anaerobic Sulfate-Reducing Bacteria (SRB) and a Comparison of Related Enzymes in Their Sulfate Reduction Pathways
Previous Article in Journal
Chryseobacterium herbae Isolated from the Rhizospheric Soil of Pyrola calliantha H. Andres in Segrila Mountain on the Tibetan Plateau
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 11
Issue 8
10.3390/microorganisms11082018
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Current Insights into the Use of Probiotics and Fatty Acids in Alleviating Depression

by
Han Gao
1,2,
Chengwei He
2,
Shuzi Xin
2,
Rongxuan Hua
3,
Yixuan Du
3,
Boya Wang
4,
Fengrong Gong
3,
Xinyi Yu
3,
Luming Pan
3,
Lei Gao
5 and
Jingdong Xu
2,*
1
Department of Clinical Laboratory, Aerospace Center Hospital, Beijing 100049, China
2
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
3
Department of Clinical Medicine, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
4
Department of Digestive Oncology, Peking University Cancer Hospital, Beijing 100044, China
5
Department of Biomedical Informatics, School of Biomedical Engineering, Capital Medical University, Beijing 100069, China
*
Author to whom correspondence should be addressed.
Microorganisms 2023, 11(8), 2018; https://doi.org/10.3390/microorganisms11082018
Submission received: 20 June 2023 / Revised: 25 July 2023 / Accepted: 25 July 2023 / Published: 5 August 2023
(This article belongs to the Section Gut Microbiota)
Browse Figures
Review Reports Versions Notes

Abstract

:
(1) Background: Depression is the most prevalent psychiatric symptom present among individuals of all ages and backgrounds, impacting an estimated 300 million people globally. Therefore, it demands a significant amount of attention when it comes to managing depression. A growing amount of data reveal that probiotics and fatty acids could be beneficial to depression. However, the opposing position maintains that they have no influence on depression. A network meta-analyses of existing datasets aid in the estimation of comparative efficacy as well as in achieving an understanding of the relative merits of different therapies. The purpose of this study was to investigate the current evidence for probiotic or fatty acid depression therapy and to establish a practical alternative for depression patients using a meta-analysis and metagenomic data from a Wistar–Kyoto (WKY) depressed rat model. (2) Methods: Probiotic data were obtained from seven randomized controlled trial studies (n = 394), and fatty acid data were obtained from 24 randomized controlled trial studies (n = 1876). Meanwhile, a metagenomics analysis of data on animal gut flora was also applied to validate the preceding evidence. (3) Results: The fatty acid studies were separated into three sections based on the duration of probiotic delivery: ≤8 weeks, 9–12 weeks, and >12 weeks. The results were as follows: for ≤8 weeks, MD = −1.65 (95% CI: −2.96–−0.15), p = 0.01; for 9–12 weeks, MD = −2.22 (95% CI: −3.03–−1.22), p < 0.001; for >12 weeks, MD = −1.23 (95% CI: −2.85–0.39), p = 0.14. Regarding the probiotics, the meta-analysis revealed MD = −2.19 (95% CI: −3.38–−2.43), p < 0.001. The research presented herein illustrates that probiotics and fatty acids may successfully lower depression scores. Additionally, the probiotics were drastically reduced in the WKY rats. (4) Conclusions: According to the data, a depression intervention utilizing probiotics outperformed the control, implying that the use of probiotics and fatty acids may be a successful strategy for depression treatment.

1. Introduction

The global prevalence of depression has increased considerably since 1990, resulting in severe disability and a loss of fulfillment in life [1,2]. Depression is characterized by a persistent sense of melancholy, social withdrawal, and/or an inability to feel pleasure (anhedonia), as well as dysfunctions such as changes in the intake of food and sleep, difficulties focusing, and irritability [3]. According to a report from the World Health Organization (WHO), depression affects around 350 million people worldwide [4]. Furthermore, depression raises the risk of suicidal behavior and mortality [5], and the total number of suicides owing to depression approaches 800,000 per year (WHO, 2017). As a result, the increasing prevalence of depression presents a huge challenge for healthcare systems, emphasizing the importance of optimizing screening, diagnosis, and therapy.
In primary care settings, a score of 2 or higher on the Patient Health Questionnaire 2 (PHQ-2) survey, which is widely utilized for diagnosis, has a sensitivity of 86% and a specificity of 78% [6]. Following a positive PHQ-2 depression result, the PHQ-9 is a diagnostic and severity evaluation tool [7]. The PHQ-9 has been approved for use in primary care settings since it is straightforward to score and can evaluate the severity of MDD. The Beck Depression Inventory and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [8], are two widely utilized tools. In terms of therapy, a wide range of antidepressants with somewhat distinct mechanisms of function are frequently employed and are available globally. Simultaneously, non-pharmacological therapies such as exercise, prebiotics, probiotics [9], yoga, fatty acids [10], self-help books, exercise, relaxation therapy, and acupuncture have received widespread acceptance due to substantial clinical evidence of their beneficial effects [11]. Meanwhile, several studies have identified different biomarkers linked to depression, such as folate [12], Vitamin D [13], zinc, iron [14,15], and nestin-1 [16].
Other studies, however, have raised questions about the usefulness of omega-3 fatty acids and probiotics in the treatment of depression in adults [17]. It has now become obvious that the enormous amount of gut microbiota may have a crucial influence on our mental health. Through animal models, dysbiosis has been demonstrated to impair vagus signal transduction and impede protein synthesis in the hippocampus, which might be reversed by rescuing the gut microbiome via the administration of specific strains of probiotics or by gradually recovering through the elimination of the relevant stressor(s) [18,19] and probiotics [20]. Lacticaseibacillus rhamnosus supplementation in rats for 28 days substantially lowered depression evaluation scores [21]. Meanwhile, 30 days of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 supplementation for 30 days can considerably lower psychological stress levels in rats and humans [22]. Individuals with MDD who received probiotics had lower Beck Depression Inventory scores [23]. Furthermore, an animal investigation into the mechanism of depression alleviation revealed that probiotics may boost tryptophan levels in the plasma while reducing serotonin concentrations in the frontal brain and cortical dopamine metabolites [24]. There are currently several types of research on depression, probiotics, and fatty acids. The benefits of probiotics and fatty acids on depression treatment, on the other hand, are still being debated. The purpose of this research is to review and analyze the existing evidence to determine whether probiotics and fatty acids have antidepressant effects.

2. Materials and Methods

2.1. Data Sources and Study Selection

All titles and abstracts were independently reviewed by pairs of academics, with no restrictions on language or year of publication. The databases and other sources, including PubMed, EMBASE, Cochrane Library, and Web of Science, were sensitively and thoroughly searched for studies from the earliest record to 1 July 2022, using the text keywords (title or abstract) and Medical Subject Headings (MeSH) terms “probiotics”, “prebiotics”, “Lactobacillus”, “Bifidobacterium”, and “depression” to identify all relevant studies. Except for the terms “fatty acids” and “depression,” the search approach of the researchers concerning fatty acids was consistent with the previous approach. Full texts were also reviewed for cases in which eligibility could not be established based on the title and abstract.

2.2. Inclusion Criteria

The following inclusion criteria were fulfilled by the studies:
(1)
A randomized controlled trial (RCT);
(2)
A clinical cohort and controls, with the clinical cohort’s intervention being the administration of probiotics or fatty acids;
(3)
Reports that utilized identical methodologies and scientific grading scales for depression;
(4)
Data reported as means ± SDs.

2.3. Extraction and Synthesis of Data

The estimates were pooled by standardizing the standard form, which included the first author’s name, the year of publication, the nation, the sample, the research procedure, the depression rating scales, probiotic species, and fatty acid descriptions.

2.4. Assessment Quality

To assess the risk of bias, Review Manager 5.4 was used, which is divided into seven domains: random order generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias.

2.5. Statistical Analysis

Review Manager version 5.4 was utilized to create the forest plots, funnel plots, and risk of bias map (the Nordic Cochrane Centre, Copenhagen, Denmark). Heterogeneity between studies was exhibited by standard χ2 tests (p-value < 0.10), and the I2 statistic revealed research heterogeneity [25,26]. I2 values of roughly 25% indicate low heterogeneity, I2 values of 50% indicate moderate heterogeneity, and I2 values of 75% indicate significant heterogeneity [26]. The random effects model incorporates heterogeneity from not only sampling but also study-level errors by using the mean of a range of actual effect values rather than a single true effect size. Fixed effects models, on the other hand, have a single real effect size that occurs across all trials, and any volatility observed is purely due to sampling error, resulting in estimates that only include within-study variance. Random effects models are more exact than fixed effects models in circumstances of substantial heterogeneity. To explore probable reasons for heterogeneity, the following criteria were planned: treatment duration, probiotic species or strain(s), and probiotic dose. The subgroup analysis was divided based on the duration of the intervention lasted. Sensitivity analyses were performed by eliminating each study sequentially to determine the influence of individual studies on total prevalence estimates. The random effects model was used to assess the influence of fatty acid delivery on depression ratings, and the findings were presented as the standardized mean difference (SMD) of 95% confidence intervals (CIs). The depression score for continuous variables, as well as the associated 95% CIs, was calculated using fixed effects models for probiotics therapy.

2.6. Metagenome Analysis

Metagenomic DNA was extracted from WKY rat feces for quantitative investigation of gut microbiota utilizing the Stool Genomic DNA Kit (GENEWIZ, Suzhou, China). To the 3’end of the purified DNA fragments, an “A” nucleotide was inserted for end-repair. Following that, palindromic forked adapters embedded with unique 8-base index sequences were attached to each end of paired-indexed Illumina dual-end adapters. To complete the development and detection of the sequencing library, target DNA fragments were screened using magnetic beads and amplified with PCR with an index at the end of the target segment. Illumina’s TruSeq ChIP Library Preparation kit was used to create sequencing libraries, and libraries were barcoded using an Illumina HiSeq2000 instrument depending on fragment size.

3. Results

Following selection based on the inclusion criteria, research relevant to the region was assessed to validate whether it was appropriate for inclusion in this review. Data were extracted from 24 RCT studies, which included 1876 samples for fatty acid treatment (as depicted in Figure 1), and 7 RCT studies that included 394 participants for probiotics treatment, with a primary diagnosis of depression according to standard diagnostic criteria such as Beck Depression Inventory-II (BDI-II), Montgomery-sberg Depression Rating Scale (MADRS), Patient Health Questionnaire (PHQ-9), Depression Interview, and Structured Hamilton Scale (HSCL-D-20), Geriatric Depression Scale (GDS) and Depression Scale of the Center for Epidemiological Studies(CES-D).

3.1. Fatty Acids Intervention

Figure 1 depicts the screening study procedure. In all, 24 studies and 1876 persons were included, with detailed information presented in Table 1. The risk of bias for the included RCTs remained low, as demonstrated in Figure 2. The depression score was lowered in the fatty acid administration vs. the placebo, with MD = −1.73 (95% CI: −3–−0.46, I2 = 65%, p = 0.008) (Figure 3 and Figure 4).
A subgroup analysis was carried out to identify potential sources of heterogeneity between studies and to evaluate the consistency of the findings across different patient subpopulations. However, several considerations should be taken when evaluating the reported effect sizes and their possible consequences. The study was then separated into three sections based on the duration of fatty acids treatment: ≤8 weeks, 9–12 weeks, and >12 weeks. As Figure 5 indicates, the ≤8 weeks, MD = −1.65 (95% CI: −2.96–−0.15), p = 0.01; 9–12 weeks, MD = −2.22 (95% CI: −3.03–−1.22), p < 0.001; >12 weeks, MD = −1.23 (95% CI: −2.85–0.39), p = 0.14. The results revealed that the lessened depression scale in the fatty acid treatment group was better than that in the placebo groups, and there was considerable statistical heterogeneity in the 9–12 weeks subgroup analysis (I2 = 71%, p < 0.001).

3.2. Probiotics Intervention

A flow diagram of probiotic-related references is presented in Figure 6 and Figure 7, and 394 participants were evaluated in total, with detailed information summarized in Table 2. According to the survey’s quality evaluation, the risk of bias for each RCT included was minor (Figure 7). The meta-analysis revealed MD = −2.19 (95% CI: −3.38–−2.43), p < 0.001, confirming that the probiotics intervention was more effective than the placebo in alleviating depression symptoms (Figure 8 and Figure 9).

3.3. Evaluation of Probiotic Content in the Rat Model of Depression

Based on the evidence presented above, we evaluated the number of depressed rats. Since the WKY rat is autonomously more susceptible to stress and represents a well-known genetic model of endogenous depression [59,60,61]. When stressed, in WKY rats, the NE system is wrongly activated in WKY rats, resulting in aberrant monoamine alterations and enhanced stress susceptibility [62,63]. As a basis, we selected the WKY rat as the depression model and the SD rat as the control sample. Furthermore, we performed metagenome analysis to assess the composition of bacteria in the feces of WKY rats and SD rats to determine whether the level of probiotics is lowered in the depression model. Figure 10 reveals that the SD rats possessed 68 unique Lactobacillus species, but the WKY rats only had nine different Lactobacillus species. Moreover, there were 28 unique species of Bifidobacterium in SD rats as well as 11 species in WKY rats. Additionally, as depicted in Figure 10, the number of commonly encountered species decreased significantly in the WKY rats as opposed to the SD rats. The foregoing findings revealed that the abundance and diversity of probiotics had dramatically decreased in WKY rats.

4. Discussion

Depression has attracted a great deal of attention owing to its broad occurrence. As a corollary, despite substantial study into its diagnosis, treatment, and origin, many elements remain obscure and are being explored. So far, three well-known key mechanisms of depression development have been identified: disruption of the hypothalamus–pituitary–adrenal (HPA) axis regulation [64] and the probable significance of adult-generated neuron persistence in the hippocampus’s dentate gyrus [65], as well as declination of the neurotransmission of brain monoamines. However, the causes of depression are not well understood. Numerous studies have demonstrated that there exists a great deal of potential biological correlates. Peripheral inflammation makers in both blood and cerebrospinal fluid have been linked to depression development in studies involving humans and animals [66]. Therefore, neuroinflammation has gained increasing attention and is regarded as a key role in depression; IL-6, IFN-α, and C-reactive protein (CRP) have been shown to be linked to depression [67,68]. In addition, evidence indicates that increased pro-inflammatory kinds of cytokines correlate to depression symptoms [69]. Overall, there is considerable evidence that immune system modifications may be one of the mechanisms through which antidepressant medicines work. There is significant evidence for a relationship between inflammatory activity and depression. Moreover, a considerable decline in sex hormones, such as estrogen and progesterone, may exacerbate the disorder’s development [70]. Another piece of research revealed that one of the reasons for depression is low serotonin levels or aberrant serotonin metabolism, which disturbs the serotonergic system [71,72,73]. Deficits in micronutrients such as vitamins (B complex, D) [74,75], omega-3 polyunsaturated fatty acids (PUFAs), and minerals (Zinc, magnesium) [76] can also contribute to depression [77,78,79].
Omega-6 and omega-3 PUFAs are routinely used to prevent or treat depression. Linoleic acid (C18:3n3) is normally transformed into two g-linolenic acids (C18:3n6), which are subsequently turned into arachidonic acids (AA, 20:4n-6 or 20:4ω6). Linolenic acid is converted into docosahexaenoic acid (DHA, 22:6n-3 or 22:6ω3) and eicosapentaenoic acid (EPA, 20:5n-4 or 20:5ω3). It has been shown that AA and DHA are structurally essential parts of the phospholipid membranes of synaptic terminals and the brain and play a vital role in neuronal membrane maintenance, neurotransmission, and signal transduction, as well as influencing the serotonin hormone metabolism, thereby influencing mood, sleep, and pleasure behaviors [80,81,82,83,84].
Long-term DHA deficiency, combined with a low level of 5-hydroxy indoleacetic acid in cerebrospinal fluid, could have an impact on brain structure and function [85], resulting in decreased receptor activities of serotonin release and reuptake, lowered serotonergic neurotransmission efficiency, and lessened serotonin metabolite [71,86,87]. Fatty acid binding proteins 5 and 7 [88], as well as the transporters Mfsd2a [89], are thought to modulate the absorption of blood DHA across the blood–brain barrier. Furthermore, cell integrity plays an integral part in DHA replenishment in the brain.
EPA is essential in the regulation of immunological and inflammatory responses. It should be highlighted that EPA inhibits prostaglandin E2 synthesis [90], NF-κB activation, and the production of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, IL-8, and IFN-γ [91], thereby diminishing the response to inflammatory stimuli [92]. Pro-inflammatory cytokines are supposed to alleviate depression by increasing tryptophan conversion to kynurenic acid and subsequently hindering tryptophan conversion to serotonin. A distinct perspective was taken on chronic stress, depression, and immunity [93]. Tryptophan is a precursor of the kynurenine pathway (KP), which plays a crucial part in the development of depression [94,95]. Females are disproportionately impacted by stress-primed inflammation, which explains why women are higher vulnerability to depression than men [96]. EPA can also enhance serotonin release by inhibiting the synthesis of PGE2, which has an inhibitory influence on serotonin release from presynaptic neurons [97,98], thereby resulting in an anti-depressive impact.
A growing body of evidence suggests that gut health is linked to psychological health, implying that the gut–brain axis exists and communicates in the gastrointestinal tract, central nervous system (CNS), autonomic nervous system, enteric nervous system, neurohormonal system, and immune system in complex and bidirectional ways [99]. Notably, the gut microbiota contributes to depression by regulating various signaling pathways implicated in the gut–brain axis, such as inflammatory responses, the host metabolism, kinase II/cyclic AMP response element-binding protein, and mitogen-activated protein (MAP) kinase signaling, Ca2+/calmodulin-dependent protein, and the endocannabinoid system [100,101,102,103,104]. With the advancement of understanding the gut microbiota–gut–brain axis, gut microbiota may play a potentially crucial role in depression diagnosis and therapy owing to their role in the bidirectional communication between the gastrointestinal tract and the brain. A disturbed microbiome balance and functional alterations owed the characteristic of increased pro-inflammatory bacteria (e.g., Desulfovibrio and Escherichia/Shigella) and decreased anti-inflammatory butyrate-producing bacteria (e.g., Bifidobacterium and Faecalibacterium). Candida albicans and Staphylococcus aureus were shown to be dramatically raised in depressed rat models, whereas Lactobacilli and Bifidobacteria were discovered to be significantly lowered [99]. Similar to what had been discovered in rat models, Bacteroidales were abundant in depressed individuals, whereas the family Lachnospiraceae was underrepresented [99]. In China, depression was associated with higher levels of Eggerthella and Acidaminococcus but lower Coprococcus and Fusicatenibacter [105].
Restoring commensal microbiota, on the other hand, may partially reverse the psychiatric disorders. Probiotics have been shown to influence a psychological trait linked to depression vulnerability and have a suppressive effect on depression. As we all know, prebiotics and probiotics have gained popularity, owing in part to their lack of cognitive side effects and few addiction instances until lately. Lactobacillus and Bifidobacterium were the most commonly utilized probiotic supplements to relieve the depressive phenotype (Table 3). Streptococcus, Bacillus, Akkermansia, and Faecalibacterium can attenuate the depressive phenotype. However, contrary statements have also asserted that ingestion of L. intestinalis, L. reuteri, and L. helveticus can cause depressive- and pessimism-like phenotypes as well as disruption of social withdrawal [106,107]. Prolonged (21-day) administration of the probiotic Bifidobacterium adolescentis, a Gram-positive anaerobic bacterium that makes up the colon microbiota in animals [108], has antidepressant properties by lowering inflammatory cytokines and normalizing the gut microbiota [109]. There are few notable studies concerning systemic and gut inflammation. Despite the potential for prebiotics and probiotics to treat these disorders, research detected an enrichment tendency for the specific strain of Lactobacillus in patients with MDD [110], implying that the line between beneficial and pathogenic bacteria in depression is blurred. Restoring a balance may be more critical than regulating germs from a certain category.
It is worth considering how probiotics might help with depression symptoms. Probiotics have been demonstrated to regulate the immune system, promote antimicrobial substance synthesis, limit harmful microorganisms competitively, and strengthen the epithelial barrier and gut mucosal adhesion [111]. Additionally, probiotics may interfere with opioid and cannabinoid receptors in gut epithelial cells, as well as calcium-dependent potassium channels in gut sensory neurons [112,113]. These receptors have a function during neuroinflammatory processes caused by glial cells, including astrocytes and microglia [114]. Probiotics, similar to fatty acids, have an influence on serotonin. Bacteria such as Bifidobacterium infantis, Streptococcus, Escherichia, and Enterococcus, can elevate serotonin levels in the brain by enhancing tryptophan availability [24]. Meanwhile, probiotics alter neurotransmitters implicated in the pathophysiology of depression. Norepinephrine (NE) is produced by Escherichia, Bacillus, and Saccharomyces, whereas dopamine is produced by Bacillus and Serratia. The impact of certain lactic acid bacteria species was on biogenic amine production by a foodborne disease [115]. Lactobacillus and Bifidobacterium can also manufacture gamma-aminobutyric acid (GABA) [116]. Probiotics’ anti-depressive impact is aided by pro-inflammatory substances as well as neurotransmitters. Oral use of the probiotic Bifidobacterium infantis 35624 results in a high level of IL-10 in the peripheral blood [117]. Besides, Lactiplantibacillus plantarum Plantarum and Bifidobacterium longum also suppress NLRP3-mediated IL-1 generation in microglia cells [118]. Lactobacillus reuteri NK33 and Bifidobacterium adolescentis NK98 have been demonstrated to lower IL-6 and corticosterone levels in the blood [119].
In this paper, there existed some limitations that restricted the preciseness of the analysis. First, perhaps most important, the divert criterion of judging and assessing depression may partly account for the heterogeneity. The patients’ different ages were another key factor that contributed to decreased accuracy. It should also be mentioned that the antidepressant was not included in all trials. Last but not least, the therapy was inconsistent across species and time. As a result, the following research should be more detailed and limited to a more manageable group. Only in this manner can scientific and meaningful research be performed.

5. Conclusions

The current study presents the most thorough meta-analysis of data from published obtaining data from published research on the effects of fatty acids or probiotics on depression. At the same time, we investigated the link between intestinal flora and depression using data from the depression rat model’s metagenome. All of these findings demonstrate that fatty acids and probiotics have a beneficial effect on depression, providing a novel treatment strategy for future clinical therapy of depressed individuals.

Author Contributions

Conceptualization, H.G. and J.X.; methodology, H.G. and L.G.; software, C.H., S.X. and R.H.; validation, H.G., L.G. and J.X.; formal analysis, F.G., X.Y. and L.P.; investigation, H.G. and L.G.; resources, B.W. and Y.D.; data curation, L.G.; writing, original draft preparation, H.G.; writing, review and editing, H.G., B.W. and J.X.; visualization, B.W. and Y.D.; supervision, J.X.; project administration, J.X.; funding acquisition, J.X. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China Grant, grant number 82174056.

Data Availability Statement

The datasets used and/or analyzed during the current investigation are accessible upon reasonable requests from the corresponding author.

Acknowledgments

Sincerely appreciate Shuiming Xiao, Institute of Traditional Chinese Medicine, China Academy of Traditional Chinese Medicine, for his generous assistance and warmly share in the metagenomic data of SD rats’ intestinal flora.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ferrari, A.J.; Charlson, F.J.; Norman, R.E.; Patten, S.B.; Freedman, G.; Murray, C.J.; Vos, T.; Whiteford, H.A. Burden of depressive disorders by country, sex, age, and year: Findings from the global burden of disease study 2010. PLoS Med. 2013, 10, e1001547. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Gore, F.M.; Bloem, P.J.; Patton, G.C.; Ferguson, J.; Joseph, V.; Coffey, C.; Sawyer, S.M.; Mathers, C.D. Global burden of disease in young people aged 10–24 years: A systematic analysis. Lancet 2011, 377, 2093–2102. [Google Scholar] [CrossRef]
  3. Nestler, E.J.; Barrot, M.; DiLeone, R.J.; Eisch, A.J.; Gold, S.J.; Monteggia, L.M. Neurobiology of depression. Neuron 2002, 34, 13–25. [Google Scholar] [CrossRef] [Green Version]
  4. World Health Organization. Depression. Available online: https://www.who.int/en/news-room/fact-sheets/detail/depression (accessed on 31 March 2023).
  5. Amidfar, M.; Reus, G.Z.; Quevedo, J.; Kim, Y.K. The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action. Eur. J. Pharmacol. 2018, 827, 103–111. [Google Scholar] [CrossRef]
  6. Arroll, B.; Goodyear-Smith, F.; Crengle, S.; Gunn, J.; Kerse, N.; Fishman, T.; Falloon, K.; Hatcher, S. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann. Fam. Med. 2010, 8, 348–353. [Google Scholar] [CrossRef] [Green Version]
  7. Levis, B.; Sun, Y.; He, C.; Wu, Y.; Krishnan, A.; Bhandari, P.M.; Neupane, D.; Imran, M.; Brehaut, E.; Negeri, Z.; et al. Accuracy of the PHQ-2 Alone and in Combination with the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. JAMA 2020, 323, 2290–2300. [Google Scholar] [CrossRef] [PubMed]
  8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR, 5th ed.; Text Revision; American Psychiatric Association Publishing: Washington, DC, USA, 2022; 1050p. [Google Scholar]
  9. Ansari, F.; Pourjafar, H.; Tabrizi, A.; Homayouni, A. The Effects of Probiotics and Prebiotics on Mental Disorders: A Review on Depression, Anxiety, Alzheimer, and Autism Spectrum Disorders. Curr. Pharm. Biotechnol. 2020, 21, 555–565. [Google Scholar] [CrossRef] [PubMed]
  10. Bae, J.H.; Kim, G. Systematic review and meta-analysis of omega-3-fatty acids in elderly patients with depression. Nutr. Res. 2018, 50, 1–9. [Google Scholar] [CrossRef] [PubMed]
  11. Mead, G.E.; Morley, W.; Campbell, P.; Greig, C.A.; McMurdo, M.; Lawlor, D.A. Exercise for depression. Cochrane Database Syst. Rev. 2009, 3, CD004366. [Google Scholar] [CrossRef] [Green Version]
  12. Bender, A.; Hagan, K.E.; Kingston, N. The association of folate and depression: A meta-analysis. J. Psychiatr. Res. 2017, 95, 9–18. [Google Scholar] [CrossRef]
  13. Gowda, U.; Mutowo, M.P.; Smith, B.J.; Wluka, A.E.; Renzaho, A.M. Vitamin D supplementation to reduce depression in adults: Meta-analysis of randomized controlled trials. Nutrition 2015, 31, 421–429. [Google Scholar] [CrossRef] [PubMed]
  14. Li, Z.; Li, B.; Song, X.; Zhang, D. Dietary zinc and iron intake and risk of depression: A meta-analysis. Psychiatry Res. 2017, 251, 41–47. [Google Scholar] [CrossRef] [PubMed]
  15. Kirsch, I.; Jakobsen, J.C. Network meta-analysis of antidepressants. Lancet 2018, 392, 1010. [Google Scholar] [CrossRef] [Green Version]
  16. Liu, M.; Shen, X.; Du, X.; Jiang, H. Plasma levels of nesfatin-1 as a new biomarker in depression in Asians: Evidence from meta-analysis. Biomarkers 2020, 25, 228–234. [Google Scholar] [CrossRef]
  17. Appleton, K.M.; Sallis, H.M.; Perry, R.; Ness, A.R.; Churchill, R. Omega-3 fatty acids for depression in adults. Cochrane Database Syst. Rev. 2015, 11, CD004692. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Dinan, T.G.; Cryan, J.F. Melancholic microbes: A link between gut microbiota and depression? Neurogastroenterol. Motil. 2013, 25, 713–719. [Google Scholar] [CrossRef]
  19. Fond, G.; Boukouaci, W.; Chevalier, G.; Regnault, A.; Eberl, G.; Hamdani, N.; Dickerson, F.; Macgregor, A.; Boyer, L.; Dargel, A.; et al. The “psychomicrobiotic”: Targeting microbiota in major psychiatric disorders: A systematic review. Pathol. Biol. 2015, 63, 35–42. [Google Scholar] [CrossRef]
  20. Kato-Kataoka, A.; Nishida, K.; Takada, M.; Kawai, M.; Kikuchi-Hayakawa, H.; Suda, K.; Ishikawa, H.; Gondo, Y.; Shimizu, K.; Matsuki, T.; et al. Fermented Milk Containing Lactobacillus casei Strain Shirota Preserves the Diversity of the Gut Microbiota and Relieves Abdominal Dysfunction in Healthy Medical Students Exposed to Academic Stress. Appl. Environ. Microbiol. 2016, 82, 3649–3658. [Google Scholar] [CrossRef] [Green Version]
  21. Bravo, J.A.; Forsythe, P.; Chew, M.V.; Escaravage, E.; Savignac, H.M.; Dinan, T.G.; Bienenstock, J.; Cryan, J.F. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad. Sci. USA 2011, 108, 16050–16055. [Google Scholar] [CrossRef]
  22. Messaoudi, M.; Lalonde, R.; Violle, N.; Javelot, H.; Desor, D.; Nejdi, A.; Bisson, J.F.; Rougeot, C.; Pichelin, M.; Cazaubiel, M.; et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br. J. Nutr. 2011, 105, 755–764. [Google Scholar] [CrossRef] [Green Version]
  23. Akkasheh, G.; Kashani-Poor, Z.; Tajabadi-Ebrahimi, M.; Jafari, P.; Akbari, H.; Taghizadeh, M.; Memarzadeh, M.R.; Asemi, Z.; Esmaillzadeh, A. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition 2016, 32, 315–320. [Google Scholar] [CrossRef] [PubMed]
  24. Desbonnet, L.; Garrett, L.; Clarke, G.; Bienenstock, J.; Dinan, T.G. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. J. Psychiatr. Res. 2008, 43, 164–174. [Google Scholar] [CrossRef] [PubMed]
  25. Higgins, J.P.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21, 1539–1558. [Google Scholar] [CrossRef] [PubMed]
  26. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [Google Scholar] [CrossRef] [Green Version]
  27. Antypa, N.; Smelt, A.H.; Strengholt, A.; Van der Does, A.J. Effects of omega-3 fatty acid supplementation on mood and emotional information processing in recovered depressed individuals. J. Psychopharmacol. 2012, 26, 738–743. [Google Scholar] [CrossRef]
  28. Bot, M.; Pouwer, F.; Assies, J.; Jansen, E.H.; Diamant, M.; Snoek, F.J.; Beekman, A.T.; de Jonge, P. Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: A randomized, double-blind placebo-controlled study. J. Affect. Disord. 2010, 126, 282–286. [Google Scholar] [CrossRef] [Green Version]
  29. Carney, R.M.; Freedland, K.E.; Rubin, E.H.; Rich, M.W.; Steinmeyer, B.C.; Harris, W.S. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: A randomized controlled trial. JAMA 2009, 302, 1651–1657. [Google Scholar] [CrossRef] [Green Version]
  30. Carney, R.M.; Freedland, K.E.; Rubin, E.H.; Rich, M.W.; Steinmeyer, B.C.; Harris, W.S. A Randomized Placebo-Controlled Trial of Omega-3 and Sertraline in Depressed Patients With or at Risk for Coronary Heart Disease. J. Clin. Psychiatry 2019, 80, 13302. [Google Scholar] [CrossRef]
  31. Chang, J.P.; Su, K.P.; Mondelli, V.; Satyanarayanan, S.K.; Yang, H.T.; Chiang, Y.J.; Chen, H.T.; Pariante, C.M. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Transl. Psychiatry 2019, 9, 303. [Google Scholar] [CrossRef] [Green Version]
  32. Dashti-Khavidaki, S.; Gharekhani, A.; Khatami, M.R.; Miri, E.S.; Khalili, H.; Razeghi, E.; Hashemi-Nazari, S.S.; Mansournia, M.A. Effects of omega-3 fatty acids on depression and quality of life in maintenance hemodialysis patients. Am. J. Ther. 2014, 21, 275–287. [Google Scholar] [CrossRef] [Green Version]
  33. Frangou, S.; Lewis, M.; McCrone, P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomised double-blind placebo-controlled study. Br. J. Psychiatry 2006, 188, 46–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Freeman, M.P.; Davis, M.; Sinha, P.; Wisner, K.L.; Hibbeln, J.R.; Gelenberg, A.J. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: A randomized placebo-controlled study. J. Affect. Disord. 2008, 110, 142–148. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Fristad, M.A.; Vesco, A.T.; Young, A.S.; Healy, K.Z.; Nader, E.S.; Gardner, W.; Seidenfeld, A.M.; Wolfson, H.L.; Arnold, L.E. Pilot Randomized Controlled Trial of Omega-3 and Individual-Family Psychoeducational Psychotherapy for Children and Adolescents With Depression. J. Clin. Child Adolesc. Psychol. 2019, 48, S105–S118. [Google Scholar] [CrossRef] [PubMed]
  36. Gabbay, V.; Freed, R.D.; Alonso, C.M.; Senger, S.; Stadterman, J.; Davison, B.A.; Klein, R.G. A Double-Blind Placebo-Controlled Trial of Omega-3 Fatty Acids as a Monotherapy for Adolescent Depression. J. Clin. Psychiatry 2018, 79, 13285. [Google Scholar] [CrossRef] [PubMed]
  37. Jahangard, L.; Sadeghi, A.; Ahmadpanah, M.; Holsboer-Trachsler, E.; Sadeghi Bahmani, D.; Haghighi, M.; Brand, S. Influence of adjuvant omega-3-polyunsaturated fatty acids on depression, sleep, and emotion regulation among outpatients with major depressive disorders-Results from a double-blind, randomized and placebo-controlled clinical trial. J. Psychiatr. Res. 2018, 107, 48–56. [Google Scholar] [CrossRef]
  38. Keshavarz, S.A.; Mostafavi, S.A.; Akhondzadeh, S.; Mohammadi, M.R.; Hosseini, S.; Eshraghian, M.R.; Chamari, M. Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial. Clin. Nutr. ESPEN 2018, 25, 37–43. [Google Scholar] [CrossRef]
  39. Lesperance, F.; Frasure-Smith, N.; St-Andre, E.; Turecki, G.; Lesperance, P.; Wisniewski, S.R. The efficacy of omega-3 supplementation for major depression: A randomized controlled trial. J. Clin. Psychiatry 2011, 72, 1054–1062. [Google Scholar] [CrossRef]
  40. Lucas, M.; Asselin, G.; Merette, C.; Poulin, M.J.; Dodin, S. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: A double-blind, placebo-controlled, randomized clinical trial. Am. J. Clin. Nutr. 2009, 89, 641–651. [Google Scholar] [CrossRef] [Green Version]
  41. Marangell, L.B.; Martinez, J.M.; Zboyan, H.A.; Kertz, B.; Kim, H.F.; Puryear, L.J. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am. J. Psychiatry 2003, 160, 996–998. [Google Scholar] [CrossRef]
  42. Mozaffari-Khosravi, H.; Yassini-Ardakani, M.; Karamati, M.; Shariati-Bafghi, S.E. Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: A randomized, double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 2013, 23, 636–644. [Google Scholar] [CrossRef]
  43. Mozurkewich, E.L.; Clinton, C.M.; Chilimigras, J.L.; Hamilton, S.E.; Allbaugh, L.J.; Berman, D.R.; Marcus, S.M.; Romero, V.C.; Treadwell, M.C.; Keeton, K.L.; et al. The Mothers, Omega-3, and Mental Health Study: A double-blind, randomized controlled trial. Am. J. Obstet. Gynecol. 2013, 208, 313.e1–313.e9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Nemets, B.; Stahl, Z.; Belmaker, R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry 2002, 159, 477–479. [Google Scholar] [CrossRef]
  45. Nishi, D.; Su, K.P.; Usuda, K.; Chang, J.P.; Hamazaki, K.; Ishima, T.; Sano, Y.; Ito, H.; Isaka, K.; Tachibana, Y.; et al. Plasma estradiol levels and antidepressant effects of omega-3 fatty acids in pregnant women. Brain Behav. Immun. 2020, 85, 29–34. [Google Scholar] [CrossRef] [PubMed]
  46. Nishi, D.; Su, K.P.; Usuda, K.; Chiang, Y.J.; Guu, T.W.; Hamazaki, K.; Nakaya, N.; Sone, T.; Sano, Y.; Tachibana, Y.; et al. The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO): Study protocol for a randomized controlled trial. BMC Psychiatry 2016, 16, 321. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Pomponi, M.; Loria, G.; Salvati, S.; Di Biase, A.; Conte, G.; Villella, C.; Righino, E.; Ciciarelli, C.; Bria, P.; La Torre, G.; et al. DHA effects in Parkinson disease depression. Basal Ganglia 2014, 4, 61–66. [Google Scholar] [CrossRef]
  48. Rogers, P.J.; Appleton, K.M.; Kessler, D.; Peters, T.J.; Gunnell, D.; Hayward, R.C.; Heatherley, S.V.; Christian, L.M.; McNaughton, S.A.; Ness, A.R. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: A randomised controlled trial. Br. J. Nutr. 2008, 99, 421–431. [Google Scholar] [CrossRef] [Green Version]
  49. Rondanelli, M.; Giacosa, A.; Opizzi, A.; Pelucchi, C.; La Vecchia, C.; Montorfano, G.; Negroni, M.; Berra, B.; Politi, P.; Rizzo, A.M. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: A double-blind, placebo-controlled, randomized clinical trial. J. Am. Coll. Nutr. 2010, 29, 55–64. [Google Scholar] [CrossRef]
  50. Su, K.P.; Huang, S.Y.; Chiu, C.C.; Shen, W.W. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 2003, 13, 267–271. [Google Scholar] [CrossRef]
  51. Su, K.P.; Huang, S.Y.; Chiu, T.H.; Huang, K.C.; Huang, C.L.; Chang, H.C.; Pariante, C.M. Omega-3 fatty acids for major depressive disorder during pregnancy: Results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2008, 69, 644–651. [Google Scholar] [CrossRef]
  52. Tajalizadekhoob, Y.; Sharifi, F.; Fakhrzadeh, H.; Mirarefin, M.; Ghaderpanahi, M.; Badamchizade, Z.; Azimipour, S. The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: A double-blind, randomized, placebo-controlled study. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261, 539–549. [Google Scholar] [CrossRef]
  53. Majeed, M.; Nagabhushanam, K.; Arumugam, S.; Majeed, S.; Ali, F. Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: A randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food Nutr. Res. 2018, 62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Chahwan, B.; Kwan, S.; Isik, A.; van Hemert, S.; Burke, C.; Roberts, L. Gut feelings: A randomised, triple-blind, placebo-controlled trial of probiotics for depressive symptoms. J. Affect. Disord. 2019, 253, 317–326. [Google Scholar] [CrossRef] [PubMed]
  55. Reininghaus, E.Z.; Platzer, M.; Kohlhammer-Dohr, A.; Hamm, C.; Morkl, S.; Bengesser, S.A.; Fellendorf, F.T.; Lahousen-Luxenberger, T.; Leitner-Afschar, B.; Schoggl, H.; et al. PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression-A Randomized Controlled Trial. Nutrients 2020, 12, 3422. [Google Scholar] [CrossRef] [PubMed]
  56. Baiao, R.; Capitao, L.P.; Higgins, C.; Browning, M.; Harmer, C.J.; Burnet, P.W.J. Multispecies probiotic administration reduces emotional salience and improves mood in subjects with moderate depression: A randomised, double-blind, placebo-controlled study. Psychol. Med. 2023, 53, 3437–3447. [Google Scholar] [CrossRef] [PubMed]
  57. Romijn, A.R.; Rucklidge, J.J.; Kuijer, R.G.; Frampton, C. A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression. Aust. N. Z. J. Psychiatry 2017, 51, 810–821. [Google Scholar] [CrossRef] [Green Version]
  58. Zhang, X.; Chen, S.; Zhang, M.; Ren, F.; Ren, Y.; Li, Y.; Liu, N.; Zhang, Y.; Zhang, Q.; Wang, R. Effects of Fermented Milk Containing Lacticaseibacillus paracasei Strain Shirota on Constipation in Patients with Depression: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 2021, 13, 2238. [Google Scholar] [CrossRef] [PubMed]
  59. Lemos, J.C.; Zhang, G.; Walsh, T.; Kirby, L.G.; Akanwa, A.; Brooks-Kayal, A.; Beck, S.G. Stress-hyperresponsive WKY rats demonstrate depressed dorsal raphe neuronal excitability and dysregulated CRF-mediated responses. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2011, 36, 721–734. [Google Scholar] [CrossRef] [Green Version]
  60. Nam, H.; Clinton, S.M.; Jackson, N.L.; Kerman, I.A. Learned helplessness and social avoidance in the Wistar-Kyoto rat. Front. Behav. Neurosci. 2014, 8, 109. [Google Scholar] [CrossRef] [Green Version]
  61. Rittenhouse, P.A.; Lopez-Rubalcava, C.; Stanwood, G.D.; Lucki, I. Amplified behavioral and endocrine responses to forced swim stress in the Wistar-Kyoto rat. Psychoneuroendocrinology 2002, 27, 303–318. [Google Scholar] [CrossRef]
  62. Pare, W.P.; Blair, G.R.; Kluczynski, J.; Tejani-Butt, S. Gender differences in acute and chronic stress in Wistar Kyoto (WKY) rats. Integr. Physiol. Behav. Sci. Off. J. Pavlov. Soc. 1999, 34, 227–241. [Google Scholar] [CrossRef]
  63. Sands, S.A.; Strong, R.; Corbitt, J.; Morilak, D.A. Effects of acute restraint stress on tyrosine hydroxylase mRNA expression in locus coeruleus of Wistar and Wistar-Kyoto rats. Brain Res. Mol. Brain Res. 2000, 75, 1–7. [Google Scholar] [CrossRef]
  64. Bao, A.M.; Swaab, D.F. The human hypothalamus in mood disorders: The HPA axis in the center. IBRO Rep. 2019, 6, 45–53. [Google Scholar] [CrossRef] [PubMed]
  65. Eliwa, H.; Belzung, C.; Surget, A. Adult hippocampal neurogenesis: Is it the alpha and omega of antidepressant action? Biochem. Pharmacol. 2017, 141, 86–99. [Google Scholar] [CrossRef] [PubMed]
  66. Raison, C.L.; Dantzer, R.; Kelley, K.W.; Lawson, M.A.; Woolwine, B.J.; Vogt, G.; Spivey, J.R.; Saito, K.; Miller, A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: Relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15, 393–403. [Google Scholar] [CrossRef] [Green Version]
  67. Haapakoski, R.; Mathieu, J.; Ebmeier, K.P.; Alenius, H.; Kivimaki, M. Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav. Immun. 2015, 49, 206–215. [Google Scholar] [CrossRef] [Green Version]
  68. Capuron, L.; Gumnick, J.F.; Musselman, D.L.; Lawson, D.H.; Reemsnyder, A.; Nemeroff, C.B.; Miller, A.H. Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2002, 26, 643–652. [Google Scholar] [CrossRef]
  69. Simpson, W.; Steiner, M.; Coote, M.; Frey, B.N. Relationship between inflammatory biomarkers and depressive symptoms during late pregnancy and the early postpartum period: A longitudinal study. Braz. J. Psychiatry 2016, 38, 190–196. [Google Scholar] [CrossRef] [Green Version]
  70. Bloch, M.; Daly, R.C.; Rubinow, D.R. Endocrine factors in the etiology of postpartum depression. Compr. Psychiatry 2003, 44, 234–246. [Google Scholar] [CrossRef]
  71. Jans, L.A.; Riedel, W.J.; Markus, C.R.; Blokland, A. Serotonergic vulnerability and depression: Assumptions, experimental evidence and implications. Mol. Psychiatry 2007, 12, 522–543. [Google Scholar] [CrossRef]
  72. Doornbos, B.; Dijck-Brouwer, D.A.; Kema, I.P.; Tanke, M.A.; van Goor, S.A.; Muskiet, F.A.; Korf, J. The development of peripartum depressive symptoms is associated with gene polymorphisms of MAOA, 5-HTT and COMT. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33, 1250–1254. [Google Scholar] [CrossRef] [PubMed]
  73. Fasching, P.A.; Faschingbauer, F.; Goecke, T.W.; Engel, A.; Haberle, L.; Seifert, A.; Voigt, F.; Amann, M.; Rebhan, D.; Burger, P.; et al. Genetic variants in the tryptophan hydroxylase 2 gene (TPH2) and depression during and after pregnancy. J. Psychiatr. Res. 2012, 46, 1109–1117. [Google Scholar] [CrossRef] [PubMed]
  74. Gur, E.B.; Gokduman, A.; Turan, G.A.; Tatar, S.; Hepyilmaz, I.; Zengin, E.B.; Eskicioglu, F.; Guclu, S. Mid-pregnancy vitamin D levels and postpartum depression. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014, 179, 110–116. [Google Scholar] [CrossRef]
  75. Robinson, M.; Whitehouse, A.J.; Newnham, J.P.; Gorman, S.; Jacoby, P.; Holt, B.J.; Serralha, M.; Tearne, J.E.; Holt, P.G.; Hart, P.H.; et al. Low maternal serum vitamin D during pregnancy and the risk for postpartum depression symptoms. Arch. Women’s Ment. Health 2014, 17, 213–219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Wojcik, J.; Dudek, D.; Schlegel-Zawadzka, M.; Grabowska, M.; Marcinek, A.; Florek, E.; Piekoszewski, W.; Nowak, R.J.; Opoka, W.; Nowak, G. Antepartum/postpartum depressive symptoms and serum zinc and magnesium levels. Pharmacol. Rep. 2006, 58, 571–576. [Google Scholar] [PubMed]
  77. Sontrop, J.; Avison, W.R.; Evers, S.E.; Speechley, K.N.; Campbell, M.K. Depressive symptoms during pregnancy in relation to fish consumption and intake of n-3 polyunsaturated fatty acids. Paediatr. Perinat. Epidemiol. 2008, 22, 389–399. [Google Scholar] [CrossRef]
  78. Golding, J.; Steer, C.; Emmett, P.; Davis, J.M.; Hibbeln, J.R. High levels of depressive symptoms in pregnancy with low omega-3 fatty acid intake from fish. Epidemiology 2009, 20, 598–603. [Google Scholar] [CrossRef]
  79. Rees, A.M.; Austin, M.P.; Owen, C.; Parker, G. Omega-3 deficiency associated with perinatal depression: Case control study. Psychiatry Res. 2009, 166, 254–259. [Google Scholar] [CrossRef]
  80. Kidd, P.M. Omega-3 DHA and EPA for cognition, behavior, and mood: Clinical findings and structural-functional synergies with cell membrane phospholipids. Altern. Med. Rev. 2007, 12, 207–227. [Google Scholar]
  81. Tassoni, D.; Kaur, G.; Weisinger, R.S.; Sinclair, A.J. The role of eicosanoids in the brain. Asia Pac. J. Clin. Nutr. 2008, 17, 220–228. [Google Scholar]
  82. Sinclair, A.J.; Begg, D.; Mathai, M.; Weisinger, R.S. Omega 3 fatty acids and the brain: Review of studies in depression. Asia Pac. J. Clin. Nutr. 2007, 16, 391–397. [Google Scholar]
  83. Maes, M.; Smith, R.; Christophe, A.; Cosyns, P.; Desnyder, R.; Meltzer, H. Fatty acid composition in major depression: Decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J. Affect. Disord. 1996, 38, 35–46. [Google Scholar] [CrossRef] [PubMed]
  84. Stoll, A.L.; Locke, C.A.; Marangell, L.B.; Severus, W.E. Omega-3 fatty acids and bipolar disorder: A review. Prostaglandins Leukot. Essent. Fat. Acids 1999, 60, 329–337. [Google Scholar] [CrossRef] [PubMed]
  85. Stillwell, W.; Shaikh, S.R.; Zerouga, M.; Siddiqui, R.; Wassall, S.R. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod. Nutr. Dev. 2005, 45, 559–579. [Google Scholar] [CrossRef] [Green Version]
  86. Lesa, G.M.; Palfreyman, M.; Hall, D.H.; Clandinin, M.T.; Rudolph, C.; Jorgensen, E.M.; Schiavo, G. Long chain polyunsaturated fatty acids are required for efficient neurotransmission in C. elegans. J. Cell Sci. 2003, 116, 4965–4975. [Google Scholar] [CrossRef] [Green Version]
  87. Grosso, G.; Galvano, F.; Marventano, S.; Malaguarnera, M.; Bucolo, C.; Drago, F.; Caraci, F. Omega-3 fatty acids and depression: Scientific evidence and biological mechanisms. Oxid. Med. Cell. Longev. 2014, 2014, 313570. [Google Scholar] [CrossRef] [Green Version]
  88. Pan, Y.; Scanlon, M.J.; Owada, Y.; Yamamoto, Y.; Porter, C.J.; Nicolazzo, J.A. Fatty Acid-Binding Protein 5 Facilitates the Blood-Brain Barrier Transport of Docosahexaenoic Acid. Mol. Pharm. 2015, 12, 4375–4385. [Google Scholar] [CrossRef] [PubMed]
  89. Nguyen, L.N.; Ma, D.; Shui, G.; Wong, P.; Cazenave-Gassiot, A.; Zhang, X.; Wenk, M.R.; Goh, E.L.; Silver, D.L. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 2014, 509, 503–506. [Google Scholar] [CrossRef]
  90. Vecchio, A.J.; Simmons, D.M.; Malkowski, M.G. Structural basis of fatty acid substrate binding to cyclooxygenase-2. J. Biol. Chem. 2010, 285, 22152–22163. [Google Scholar] [CrossRef] [Green Version]
  91. Jazayeri, S.; Keshavarz, S.A.; Tehrani-Doost, M.; Djalali, M.; Hosseini, M.; Amini, H.; Chamari, M.; Djazayery, A. Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res. 2010, 178, 112–115. [Google Scholar] [CrossRef]
  92. Lynch, A.M.; Loane, D.J.; Minogue, A.M.; Clarke, R.M.; Kilroy, D.; Nally, R.E.; Roche, O.J.; O’Connell, F.; Lynch, M.A. Eicosapentaenoic acid confers neuroprotection in the amyloid-beta challenged aged hippocampus. Neurobiol. Aging 2007, 28, 845–855. [Google Scholar] [CrossRef]
  93. Reigstad, C.S.; Salmonson, C.E.; Rainey, J.F., 3rd; Szurszewski, J.H.; Linden, D.R.; Sonnenburg, J.L.; Farrugia, G.; Kashyap, P.C. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J. 2015, 29, 1395–1403. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Clarke, G.; Stilling, R.M.; Kennedy, P.J.; Stanton, C.; Cryan, J.F.; Dinan, T.G. Minireview: Gut microbiota: The neglected endocrine organ. Mol. Endocrinol. 2014, 28, 1221–1238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Reus, G.Z.; Jansen, K.; Titus, S.; Carvalho, A.F.; Gabbay, V.; Quevedo, J. Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies. J. Psychiatr. Res. 2015, 68, 316–328. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Bekhbat, M.; Howell, P.A.; Rowson, S.A.; Kelly, S.D.; Tansey, M.G.; Neigh, G.N. Chronic adolescent stress sex-specifically alters central and peripheral neuro-immune reactivity in rats. Brain Behav. Immun. 2019, 76, 248–257. [Google Scholar] [CrossRef] [PubMed]
  97. Gunther, J.; Schulte, K.; Wenzel, D.; Malinowska, B.; Schlicker, E. Prostaglandins of the E series inhibit monoamine release via EP3 receptors: Proof with the competitive EP3 receptor antagonist L-826,266. Naunyn Schmiedebergs Arch. Pharmacol. 2010, 381, 21–31. [Google Scholar] [CrossRef]
  98. Patrick, R.P.; Ames, B.N. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: Relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB J. 2015, 29, 2207–2222. [Google Scholar] [CrossRef] [Green Version]
  99. Nikolova, V.; Zaidi, S.Y.; Young, A.H.; Cleare, A.J.; Stone, J.M. Gut feeling: Randomized controlled trials of probiotics for the treatment of clinical depression: Systematic review and meta-analysis. Ther. Adv. Psychopharmacol. 2019, 9, 2045125319859963. [Google Scholar] [CrossRef] [Green Version]
  100. Liu, L.; Wang, H.; Rao, X.; Yu, Y.; Li, W.; Zheng, P.; Zhao, L.; Zhou, C.; Pu, J.; Yang, D.; et al. Comprehensive analysis of the lysine acetylome and succinylome in the hippocampus of gut microbiota-dysbiosis mice. J. Adv. Res. 2021, 30, 27–38. [Google Scholar] [CrossRef]
  101. Zheng, P.; Wu, J.; Zhang, H.; Perry, S.W.; Yin, B.; Tan, X.; Chai, T.; Liang, W.; Huang, Y.; Li, Y.; et al. The gut microbiome modulates gut-brain axis glycerophospholipid metabolism in a region-specific manner in a nonhuman primate model of depression. Mol. Psychiatry 2021, 26, 2380–2392. [Google Scholar] [CrossRef]
  102. Chevalier, G.; Siopi, E.; Guenin-Mace, L.; Pascal, M.; Laval, T.; Rifflet, A.; Boneca, I.G.; Demangel, C.; Colsch, B.; Pruvost, A.; et al. Effect of gut microbiota on depressive-like behaviors in mice is mediated by the endocannabinoid system. Nat. Commun. 2020, 11, 6363. [Google Scholar] [CrossRef]
  103. Wang, H.; Liu, L.; Rao, X.; Zeng, B.; Yu, Y.; Zhou, C.; Zeng, L.; Zheng, P.; Pu, J.; Xu, S.; et al. Integrated phosphoproteomic and metabolomic profiling reveals perturbed pathways in the hippocampus of gut microbiota dysbiosis mice. Transl. Psychiatry 2020, 10, 346. [Google Scholar] [CrossRef] [PubMed]
  104. Liu, Y.; Wang, H.; Gui, S.; Zeng, B.; Pu, J.; Zheng, P.; Zeng, L.; Luo, Y.; Wu, Y.; Zhou, C.; et al. Proteomics analysis of the gut-brain axis in a gut microbiota-dysbiosis model of depression. Transl. Psychiatry 2021, 11, 568. [Google Scholar] [CrossRef] [PubMed]
  105. Dai, D.; Zhu, J.; Sun, C.; Li, M.; Liu, J.; Wu, S.; Ning, K.; He, L.J.; Zhao, X.M.; Chen, W.H. GMrepo v2: A curated human gut microbiome database with special focus on disease markers and cross-dataset comparison. Nucleic Acids Res. 2022, 50, D777–D784. [Google Scholar] [CrossRef] [PubMed]
  106. Wang, S.; Ishima, T.; Zhang, J.; Qu, Y.; Chang, L.; Pu, Y.; Fujita, Y.; Tan, Y.; Wang, X.; Hashimoto, K. Ingestion of Lactobacillus intestinalis and Lactobacillus reuteri causes depression- and anhedonia-like phenotypes in antibiotic-treated mice via the vagus nerve. J. Neuroinflammation 2020, 17, 241. [Google Scholar] [CrossRef]
  107. Partrick, K.A.; Rosenhauer, A.M.; Auger, J.; Arnold, A.R.; Ronczkowski, N.M.; Jackson, L.M.; Lord, M.N.; Abdulla, S.M.; Chassaing, B.; Huhman, K.L. Ingestion of probiotic (Lactobacillus helveticus and Bifidobacterium longum) alters intestinal microbial structure and behavioral expression following social defeat stress. Sci. Rep. 2021, 11, 3763. [Google Scholar] [CrossRef]
  108. Duranti, S.; Milani, C.; Lugli, G.A.; Mancabelli, L.; Turroni, F.; Ferrario, C.; Mangifesta, M.; Viappiani, A.; Sanchez, B.; Margolles, A.; et al. Evaluation of genetic diversity among strains of the human gut commensal Bifidobacterium adolescentis. Sci. Rep. 2016, 6, 23971. [Google Scholar] [CrossRef] [Green Version]
  109. Guo, Y.; Xie, J.P.; Deng, K.; Li, X.; Yuan, Y.; Xuan, Q.; Xie, J.; He, X.M.; Wang, Q.; Li, J.J.; et al. Prophylactic Effects of Bifidobacterium adolescentis on Anxiety and Depression-Like Phenotypes After Chronic Stress: A Role of the Gut Microbiota-Inflammation Axis. Front. Behav. Neurosci. 2019, 13, 126. [Google Scholar] [CrossRef] [Green Version]
  110. Gao, J.; Zhao, L.; Cheng, Y.; Lei, W.; Wang, Y.; Liu, X.; Zheng, N.; Shao, L.; Chen, X.; Sun, Y.; et al. Probiotics for the treatment of depression and its comorbidities: A systemic review. Front. Cell. Infect. Microbiol. 2023, 13, 1167116. [Google Scholar] [CrossRef]
  111. Bermudez-Brito, M.; Plaza-Diaz, J.; Munoz-Quezada, S.; Gomez-Llorente, C.; Gil, A. Probiotic mechanisms of action. Ann. Nutr. Metab. 2012, 61, 160–174. [Google Scholar] [CrossRef]
  112. Rousseaux, C.; Thuru, X.; Gelot, A.; Barnich, N.; Neut, C.; Dubuquoy, L.; Dubuquoy, C.; Merour, E.; Geboes, K.; Chamaillard, M.; et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 2007, 13, 35–37. [Google Scholar] [CrossRef]
  113. Sanders, M.E. Impact of probiotics on colonizing microbiota of the gut. J. Clin. Gastroenterol. 2011, 45, S115–S119. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Hofford, R.S.; Russo, S.J.; Kiraly, D.D. Neuroimmune mechanisms of psychostimulant and opioid use disorders. Eur. J. Neurosci. 2019, 50, 2562–2573. [Google Scholar] [CrossRef]
  115. Holzer, P.; Farzi, A. Neuropeptides and the microbiota-gut-brain axis. Adv. Exp. Med. Biol. 2014, 817, 195–219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  116. Schousboe, A.; Waagepetersen, H.S. GABA: Homeostatic and pharmacological aspects. Prog. Brain Res. 2007, 160, 9–19. [Google Scholar] [CrossRef] [PubMed]
  117. Bilbo, S.D.; Schwarz, J.M. The immune system and developmental programming of brain and behavior. Front. Neuroendocrinol. 2012, 33, 267–286. [Google Scholar] [CrossRef] [Green Version]
  118. Mitchell, K.T.; Larson, P.; Starr, P.A.; Okun, M.S.; Wharen, R.E., Jr.; Uitti, R.J.; Guthrie, B.L.; Peichel, D.; Pahwa, R.; Walker, H.C.; et al. Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. Park. Relat. Disord. 2019, 60, 126–132. [Google Scholar] [CrossRef]
  119. Jang, H.M.; Lee, K.E.; Kim, D.H. The Preventive and Curative Effects of Lactobacillus reuteri NK33 and Bifidobacterium adolescentis NK98 on Immobilization Stress-Induced Anxiety/Depression and Colitis in Mice. Nutrients 2019, 11, 819. [Google Scholar] [CrossRef] [Green Version]
Microorganisms 11 02018 g001
Figure 1. The search process and the screening of the articles for identifying the eligible studies. 24 RCTs were involved in the analysis.
Figure 1. The search process and the screening of the articles for identifying the eligible studies. 24 RCTs were involved in the analysis.
Microorganisms 11 02018 g001
Microorganisms 11 02018 g002
Figure 2. Risk of bias of included studies in fatty acid treatments using the Cochrane Collaboration’s tool. Risk of bias graph: each risk of bias item was presented as percentages in all included studies and risk of bias summary.
Figure 2. Risk of bias of included studies in fatty acid treatments using the Cochrane Collaboration’s tool. Risk of bias graph: each risk of bias item was presented as percentages in all included studies and risk of bias summary.
Microorganisms 11 02018 g002
Microorganisms 11 02018 g003
Figure 3. The forest plot from included studies: probiotics vs. placebo. ♦ represents the total Mean Difference. The green square represents Mean Difference and its size reveals weight. The black line represents 95% CI.
Figure 3. The forest plot from included studies: probiotics vs. placebo. ♦ represents the total Mean Difference. The green square represents Mean Difference and its size reveals weight. The black line represents 95% CI.
Microorganisms 11 02018 g003
Microorganisms 11 02018 g004
Figure 4. A funnel plot of included research refers to probiotic treatment.
Figure 4. A funnel plot of included research refers to probiotic treatment.
Microorganisms 11 02018 g004
Microorganisms 11 02018 g005
Figure 5. Forest plot of subgroups relating to fatty acids versus placebo: influence on depression scores. The results revealed that the lessened depression scale in the fatty acid treatment group was better than that in the placebo group. ♦ represents the total Mean Difference. The green square represents Mean Difference and its size reveals weight. The black line represents 95% CI.
Figure 5. Forest plot of subgroups relating to fatty acids versus placebo: influence on depression scores. The results revealed that the lessened depression scale in the fatty acid treatment group was better than that in the placebo group. ♦ represents the total Mean Difference. The green square represents Mean Difference and its size reveals weight. The black line represents 95% CI.
Microorganisms 11 02018 g005
Microorganisms 11 02018 g006
Figure 6. Flow diagram depicting the therapeutic search and selection technique for probiotics. 7 RCTs were included in the analysis.
Figure 6. Flow diagram depicting the therapeutic search and selection technique for probiotics. 7 RCTs were included in the analysis.
Microorganisms 11 02018 g006
Microorganisms 11 02018 g007
Figure 7. Risk of bias of illustrated studies in probiotics therapy using the Cochrane Collaboration tool. Risk of bias graph: each risk of bias item was presented as percentages in all analyzed investigations and risk of bias summary.
Figure 7. Risk of bias of illustrated studies in probiotics therapy using the Cochrane Collaboration tool. Risk of bias graph: each risk of bias item was presented as percentages in all analyzed investigations and risk of bias summary.
Microorganisms 11 02018 g007
Microorganisms 11 02018 g008
Figure 8. Forest plot of depression scores from included studies referring probiotics vs. placebo. The probiotics intervention was more effective than the placebo in alleviating depression symptoms. ♦ represents the total Mean Difference. The green square represents Mean Difference and its size reveals weight. The black line represents 95% CI.
Figure 8. Forest plot of depression scores from included studies referring probiotics vs. placebo. The probiotics intervention was more effective than the placebo in alleviating depression symptoms. ♦ represents the total Mean Difference. The green square represents Mean Difference and its size reveals weight. The black line represents 95% CI.
Microorganisms 11 02018 g008
Microorganisms 11 02018 g009
Figure 9. Funnel plot of included probiotics studies.
Figure 9. Funnel plot of included probiotics studies.
Microorganisms 11 02018 g009
Microorganisms 11 02018 g010
Figure 10. Venn and Heatmap revealed the probiotics content in the WKY rats and SD rats. The abundance and diversity of probiotics had decreased in WKY rats.
Figure 10. Venn and Heatmap revealed the probiotics content in the WKY rats and SD rats. The abundance and diversity of probiotics had decreased in WKY rats.
Microorganisms 11 02018 g010
Table 1. Characteristics of the included studies and their interventions upon fatty acid administration.
Table 1. Characteristics of the included studies and their interventions upon fatty acid administration.
Author
Year		CountrySample
(Female)		Depression CriterionDepression AssessmentsFatty AcidMethodologyRef.
Antypa, N. 2012 Netherlands71 (58)Beck Depression Inventory-II (BDI-II)BDI-II2.3 g of n-3 PUFA (including 1.74 g eicosapentaenoic acid (EPA) + 0.25 g docosahexaenoic acid (DHA) for 4 wDouble-blind; concealment allocation without statement;
other anti-depressants with permission.		[27]
M Bot 2010Netherlands25 (13)Composite International Diagnostic InterviewMontgomery Åsberg Depression Rating Scale (MADRS)omega-3 (E-EPA) (1 g/day) for 12 wDouble-blind; concealment allocation without statement; other anti-depressants with permission.[28]
Robert M Carney 2009USA122 (41)Patient Health Questionnaire(PHQ-9)/BDI-II/Depression Interview and Structured Hamilton (DISH)BDI-II/Hamilton Rating Scale for Depression (HAM-D)930 mg of EPA and 750 mg of DHA for 10 wDouble-blind;
other anti-depressants without permission.		[29]
Carney, R. M., 2019USA144 (56)PHQ-9 and DISHBDI-II/HAM-D/PHQ-950 mg/day of sertraline and 2 g/day of EPA for 10 wDouble-blind; without statement (permission) of concealment allocation/other anti-depressants[30]
Jane Pei- Chen Chang, 2019China59 (38)HAMDBDI/HAMD2 g per day of EPA and 1 g of DHA for 12 wDouble-blind; without statement (permission) concealment allocation is/other anti-depressants [31]
Simin Dashti-Khavidaki, 2014Iran34 (17)BDIBDI180 mg EPA and 120 mg DHA for 4 mDouble-blind; without statement (permission) of concealment allocation/
other anti-depressants		[32]
Frangou, S. 2006British51 (38)HRSDHRSD1 g/day (n = 24) or 2 g/day (n = 25) of ethyl-EPA for 12 wDouble-blind; without statement (permission) of concealment allocation/other anti-depressants[33]
Freeman, Marlene P. 2008USA51 (51)Structured Clinical Interview for DSM-IV (SCID)HAM-D and Edinburgh Postnatal Depression Scale (EPDS)1.9 g/day EPA and DHA for 8 wDouble-blind; without statement (permission) of concealment allocation/other anti-depressants [34]
Mary A. Fristad, 2016USA36 (21)DSM-IV/Children’s Depression Rating Scale-Revised(CDRS-R)CDRS-R350 mg EPA 50 mg DHA, 68 mg other Ω3 (total 1870 mg) for 12 wDouble-blind; without statement(permission) of concealment allocation/other anti-depressants [35]
Vilma Gabbay 2018USA51 (28)Clinical Global Impressions—Improvement (CGI-I)CDRS-R/BDI-IIIncreased 0.6 g/d every 2 weeks (min:1.2 maximum possible dose of 3.6 g/d, combined EPA 2.4 g plus DHA 1.2 gDouble-Blind; without statement(permission) of concealment allocation/other anti-depressants [36]
Leila Jahangard, 2018Iran50 (34)DSM 5BDI/MADS1080 mg EPA, and 720 mg DHA per day for 12 wDouble-blind; without statement(permission) of concealment allocation is not stated/other anti-depressants [37]
Seyed Ali Keshavarz, 2018Iran55 (55)DSM-5BDI1080 mg EPA, and 720 mg DHA per day for 12 wDouble-blind, concealment allocation is not stated; other anti-depressants are not allowed.[38]
Lesperance, Francois, 2011Canada432 (296)Inventory of Depressive Symptomatology(IDS-SR30)IDS-SR30
MADRS		1050 mg/d of EPA and 150 mg/d of DHA for 8 wDouble-blind; without statement(permission) of concealment allocation/other anti-depressants.[39]
Lucas, M. 2009USA120 (120)Psychological General Well-Being (PGWB)20-item Hopkins Symptom Checklist Depression Scale (HSCL-D-20)/HAM-D-211.05 g E-EPA/d plus 0.15 g EHA/d for 8 wDouble-blind; without statement(permission) of concealment allocation/
other anti-depressants 		[40]
Lauren B. Marangell, M.D. 2003USA35 DSM-IVMADRS2 g/day of DHA for 6 w.Double-blind; without statement(permission) of concealment allocation is not stated/other anti-depressants [41]
Mozaffari-Khosravi, Hassan, 2013Iran46 (26)DSM-IVHDRS1 g/d of EPA or DHA for 12 wDouble-blind; without statement(permission) of concealment allocation/other anti-depressants [42]
Mozurkewich, E. L. 2013USA80 (80)BDIBDIEPA-rich fish oil supplementation (1060 mg EPA plus 274 mg DHA)Double-blind; without statement(permission) of concealment allocation/other anti-depressants [43]
Nemets, B. 2002Israel20 (17)DSM-IVHDRS2 g/day E-EPA for 4 wDouble-blind; without statement(permission) of concealment allocation/other anti-depressants [44]
Nishi, D. 2020Japan and Taiwan100 (100)EPDSHAMD1800 mg omega-3 fatty acids (1206 mg EPA and 609 mg DHA) for 12 weeksDouble-blind; without a statement(permission) of concealment allocation, but permitted other anti-depressants[45]
Nishi, D. 2016Japan and Taiwan31 (31)EPDSHAMD1206 mg EPA and 609 mg DHA daily for 12 wDouble-blind; without statement concealment allocation; but permitted other anti-depressants.[46]
Pomponi, M. 2014Italy24 (11)DSM-IVHDRS800 mg/d DHA and 290 mg/d eicosapentaenoic acid for 6 mDouble-blind; without statement(permission) of concealment allocation is not stated/other anti-depressants[47]
Rogers, Peter J. 2008UK190DASS depressionDASS depression/BDI630 mg EPA, 850 mg DHA, 870 mg olive oil for 12 wDouble-blind; without statement(permission) of concealment allocation/other anti-depressants [48]
Rondanelli, Mariangela, 2010Italy46 (46)Geriatric Depression Scale (GDS)GDS1.67 g of EPA and 0.83 g of DHA for 8 wDouble-blind; without statement(permission) of concealment allocation/other anti-depressants[49]
Su, K. P. 2003China22 (18)HRSD/
DSM-IV		HRSD440 mg of EPA and 220 mg of DHA
for 8 w		Double-blind; without statement(permission) of concealment allocation/other anti-depressants[50]
Su, K. P., 2008China24 (24)EPDSHAMD2.2 g of EPA and 1.2 g of DHA for 8 weeksDouble-blind; without statement(permission) of concealment allocation/other anti-depressants [51]
Tajalizadekhoob, Yaser, 2011Iran66 (46)Geriatric Depression Scale-15 (GDS-15)GDS-15180 mg eicosapentaenoic acid (EPA) and 120 mg DHA for 6 monthsDouble-blind; without statement(permission) of concealment allocation/other anti-depressants.[52]
Table 2. Characteristics of included studies on probiotics pharmaceutical study.
Table 2. Characteristics of included studies on probiotics pharmaceutical study.
Author
Year		CountrySample
(Female)		Depression Criterion Depression CriterionProbioticsMethodologyRef.
Akkasheh, G. 2016Iran40 (34)DSM-IV/HDRS BDILactobacillus acidophilus (2 × 109 CFU/g), Lacticaseibacillus casei (2 × 109 CFU/g), and Bifidobacterium bifidum (2 × 109 CFU/g) for 8 wDouble-blind; without statement (permission) of other antidepressant drugs [23]
Arumugam, S. 2018India40 (34)Diagnostic and Statistical Manual of Mental DisordersHAM-D/MADRS/Center for Epidemiological Studies Depression Scale (CES-D)Bacillus coagulans MTCC 5856 (600 mg) for 90 dDouble-blind; without statement of other antidepressant drugs [53]
Bahia Chahwan, 2019Australia71 (49)BDI-IIBDI2 g Ecologic®Barrier (2.5 × 109 CFU/g) is constituted of the following nine bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, L. acidophilus W37, Levilactobacillus brevis W63, Lacticaseibacillus casei W56, Ligilactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58 (total cell count 1 × 1010 CFU/day) for 8 wTriple-blinded; without permission of other antidepressant drugs[54]
Reininghaus, E. Z. 2020Austria61 (47)HAMD/
BDI-II		HAMD/
BDI-II		Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lacticaseibacillus casei W56, Lacticaseibacillus paracasei W20, Lactiplantibacillus plantarum W62, Ligilactobacillus salivarius W24 and Lactococcus lactis W19 for 28 dDouble-Blind; with permission of other antidepressant drugs [55]
Rita Baião 2021UK71 (45)PHQ-9PHQ-9Four capsules. The probiotic (Bio-Kult® Advanced, ADM Protexin Ltd.), consisted of 14 species of bacteria, (Bacillus subtilis PXN® 21, Bifidobacterium bifidum PXN® 23, Bifidobacterium breve PXN® 25, Bifidobacterium infantis PXN® 27, B. longum PXN® 30, Lactobacillus acidophilus PXN® 35, Lactobacillus delbrueckii ssp. bulgaricus PXN® 39, Lacticaseibacillus casei PXN® 37, Lactiplantibacillus plantarum PXN® 47, Lacticaseibacillus rhamnosus PXN® 54, Lactobacillus helveticus PXN® 45, Ligilactobacillus salivarius PXN® 57, Lactococcus lactis ssp. lactis PXN® 63, Streptococcus thermophilus PXN® 66), encapsulated at 2 × 109 CFU for 4 wDouble-blind, without permission of other antidepressant drugs[56]
Romijn, A. R., 2017New Zealand79 (62)Quick Inventory of Depressive Symptomatology (QIDS-SR16)/DASS-42MADRSLactobacillus helveticus R0052B. longum R0175 ≥ 3 × 109 CFU for 8 wDouble-blind; without permission of other antidepressant drugs[57]
Zhang, X., 2021China69 (44)DSM-5BDI/HAMD100 mL of a Lacticaseibacillus casei
Shirota beverage (108 CFU/mL) for 9 w		Double-Blind; without permission of other antidepressant drugs[58]
Table 3. Summary of the mechanism of probiotics on depression.
Table 3. Summary of the mechanism of probiotics on depression.
ProbioticsStrainPatients/Animal ModelsMechanism
1Bifidobacterium LongumBifidobacterium longum (strain) 1714Patients/Rat modelsMediating vagal tone/Increasing in brain-derived neurotrophic factor (BDNF)
2Lacticaseibacillus rhamnosus Rat modelsAltering the neurotransmission of GABA
3Lactobacillus HelveticusLactobacillus helveticus (strain NS8)Rat modelsReducing blood pressure/Decreasing neuroinflammation
4Lactiplantibacillus plantarumLactiplantibacillus plantarum C29Rat modelsIncreasing BDNF/Decreasing inflammation
5Bifidobacterium Animalis Rat modelsInhibiting and/or reducing neuroinflammation
6Lacticaseibacillus caseiLacticaseibacillus casei Shirota/Lacticaseibacillus casei W56Patients
7Bifidobacterium Infantis-Rat modelsModulating monoamine (serotonin and dopamine)/reducing inflammatory
8Bifidobacterium BreveBifidobacterium breve 1205/Levilactobacillus brevis W63Patients/Rat modelsUnclear
9Lactobacillus AcidophilusLactobacillus acidophilus NCFMRat modelsUpregulating peripheral (and possibly central) CB2 receptors/modulating the cannabinoid and mu-opioid receptor
10Trans-Galactooligosaccharides-PatientsUnclear
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gao, H.; He, C.; Xin, S.; Hua, R.; Du, Y.; Wang, B.; Gong, F.; Yu, X.; Pan, L.; Gao, L.; et al. Current Insights into the Use of Probiotics and Fatty Acids in Alleviating Depression. Microorganisms 2023, 11, 2018. https://doi.org/10.3390/microorganisms11082018

AMA Style

Gao H, He C, Xin S, Hua R, Du Y, Wang B, Gong F, Yu X, Pan L, Gao L, et al. Current Insights into the Use of Probiotics and Fatty Acids in Alleviating Depression. Microorganisms. 2023; 11(8):2018. https://doi.org/10.3390/microorganisms11082018

Chicago/Turabian Style

Gao, Han, Chengwei He, Shuzi Xin, Rongxuan Hua, Yixuan Du, Boya Wang, Fengrong Gong, Xinyi Yu, Luming Pan, Lei Gao, and et al. 2023. "Current Insights into the Use of Probiotics and Fatty Acids in Alleviating Depression" Microorganisms 11, no. 8: 2018. https://doi.org/10.3390/microorganisms11082018

APA Style

Gao, H., He, C., Xin, S., Hua, R., Du, Y., Wang, B., Gong, F., Yu, X., Pan, L., Gao, L., & Xu, J. (2023). Current Insights into the Use of Probiotics and Fatty Acids in Alleviating Depression. Microorganisms, 11(8), 2018. https://doi.org/10.3390/microorganisms11082018

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop